MediFind

Find a Doctor

Zeev E. Estrov

Physicians Referral Service
Oncology, Internal Medicine
Male
Practicing approx. 45 years

Bio


Zeev Estrov is an Oncologist and an Internal Medicine specialist in Houston, Texas. He has been an author on 279 peer reviewed articles and participated in 1 clinical trials in the past 15 years. Dr. Estrov's top three areas of expertise are Chronic Lymphocytic Leukemia, Chronic B-Cell Leukemia, and Acute Myeloblastic Leukemia without Maturation. He is licensed to treat patients in TX.

Contact

Houston, TX 77030, US

Latest Research


Latest Advance
Study
  • Condition: Acute Lymphoblastic Leukemia
  • Journal: American journal of hematology
  • Treatment Used: Liposomal Vincristine
  • Number of Patients: 31
  • Published —
In this study, researchers evaluated the outcomes of using liposomal vincristine in combination with intensive chemotherapy for the treatment of acute lymphoblastic leukemia.
Latest Advance
Study
  • Condition: Chronic Myeloid Leukemia
  • Journal: Cancer
  • Treatment Used: Dasatinib
  • Number of Patients: 149
  • Published —
This study evaluated the effectiveness of dasatinib to treat patients with chronic myeloid leukemia.
Latest Advance
Study
  • Condition: Chronic-phase Chronic Myeloid Leukemia
  • Journal: Cancer
  • Treatment Used: Nilotinib
  • Number of Patients: 122
  • Published —
In this study, researchers evaluated the long term results of taking nilotinib 400 mg twice daily for the treatment of chronic-phase chronic myeloid leukemia.
Latest Advance
Study
  • Condition: Newly Diagnosed Chronic-phase Chronic Myeloid Leukemia
  • Journal: Cancer
  • Treatment Used: lower dose dasatinib as frontline therapy
  • Number of Patients: 83
  • Published —
The aim of this study was to update the long-term follow-up results of dasatinib at 50 mg daily as frontline therapy for chronic-phase chronic myeloid leukemia.
Latest Advance
Study
  • Condition: Chronic Myeloid Leukemia (CML)
  • Journal: Cancer medicine
  • Treatment Used: Generic Imatinib after Switching from Original Imatinib
  • Number of Patients: 38
  • Published —
This review of medical records of patients diagnosed with chronic myeloid leukemia (CML) in the chronic phase who were treated with original imatinib from the year 2000 to 2017, and who were subsequently switched to generic imatinib.
Latest Advance
Study
  • Condition: Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
  • Journal: The Lancet. Haematology
  • Treatment Used: Idarubicin, Cytarabine, and Nivolumab
  • Number of Patients: 44
  • Published —
This study tested the safety and efficacy of using idarubicin, cytarabine, and nivolumab to treat patients with acute myeloid leukemia or high-risk myelodysplastic syndrome.
Latest Advance
Study
  • Condition: Chronic lymphocytic leukemia
  • Journal: The New England journal of medicine
  • Treatment Used: Ibrutinib and Venetoclax
  • Number of Patients: 80
  • Published —
The study aimed to determine the effects of using Ibrutinib and Venetoclax as a first-line treatment of chronic lymphocytic leukemia.
Latest Advance
Study
  • Condition: Chronic myeloid leukemia
  • Journal: Blood advances
  • Treatment Used: Tyrosine kinase inhibitors
  • Number of Patients: 531
  • Published —
The study researched the side effects of patients with chronic myeloid leukemia being treated with tyrosine kinase inhibitors.
Latest Advance
Study
  • Condition: Older Patients With Newly Diagnosed Acute Myeloid Leukemia
  • Journal: The Lancet. Haematology
  • Treatment Used: 5-day versus 10-day schedule of decitabine
  • Number of Patients: 71
  • Published —
The purpose of the study was to assess outcomes in older patients with newly diagnosed acute myeloid leukemia who received a 5-day schedule versus a 10-day schedule of decitabine.
Latest Advance
Study
  • Condition: Chronic Lymphocytic Leukemia
  • Journal: Blood
  • Treatment Used: Ibrutinib vs. Ibrutinib plus Rituximab
  • Number of Patients: 208
  • Published —
This study compared ibrutinib versus ibrutinib plus rituximab in patients with chronic lymphocytic leukemia.
Latest Advance
Study
  • Condition: Higher-Risk Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML) after Failure of Hypomethylating Agents
  • Journal: American journal of hematology
  • Treatment Used: Omacetaxine Mepesuccinate (OM)
  • Number of Patients: 42
  • Published —
This study evaluated omacetaxine mepesuccinate (OM) in patients with myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML) who had previously failed or been intolerant to hypomethylating agents (HMAs).
Latest Advance
Study
  • Condition: Aplastic Anemia
  • Journal: Cancer
  • Treatment Used: Addition Of Eltrombopag To Immunosuppressive Therapy
  • Number of Patients: 38
  • Published —
This study evaluated standard immunosuppressive therapy (IST; medicines that lower the body's ability to reject a transplanted organ) in newly diagnosed patients with severe aplastic anemia (AA; your body stops producing enough new blood cells).
Latest Advance
Study
  • Condition: Myelofibrosis
  • Journal: Blood
  • Treatment Used: ruxolitinib in combination with azacitidine
  • Number of Patients: 46
  • Published —
This study aim to evaluate ruxolitinib in combination with azacitidine in patients with myelofibrosis.
Latest Advance
Study
  • Condition: Elderly Patients With Acute Myeloid Leukemia
  • Journal: The Lancet. Haematology
  • Treatment Used: Cladribine and low-dose cytarabine alternating with decitabine
  • Number of Patients: 118
  • Published —
The purpose of the study was to determine the safety and efficacy of Cladribine and low-dose cytarabine alternating with decitabine in treating elderly patients with acute myeloid leukemia.
Latest Advance
Study
  • Condition: Relapsed/Refractory Acute Myeloid Leukemia
  • Journal: Acta haematologica
  • Treatment Used: Erlotinib
  • Number of Patients: 29
  • Published —
The research aimed to determine the effects of erlotinib on relapsed/refractory acute myeloid leukemia.
Latest Advance
Study
  • Condition: Older Patients with Untreated FLT3-ITD Mutated Acute Myeloid Leukemia
  • Journal: American journal of hematology
  • Treatment Used: Sorafenib and 5-azacytidine
  • Number of Patients: 27
  • Published —
The study compared the combination of Sorafenib and 5-azacytidine in treating older patients with untreated FLT3-ITD mutated acute myeloid leukemia.
Latest Advance
Study
  • Condition: Myelodysplastic Syndrome/Myeloproliferative Neoplasms (MDS/MPNs)
  • Journal: American journal of hematology
  • Treatment Used: Ruxolitinib with Azacytidine
  • Number of Patients: 35
  • Published —
This study evaluated ruxolitinib and azacytidine in the treatment of patients with myelodysplastic syndrome/myeloproliferative neoplasms (MDS/MPNs).

Clinical Trials


Clinical Trial
Drug
  • Status: Recruiting
  • Study Type: Drug
  • Participants: 20
  • Start Date: December 2, 2016
A Phase IIa Study of BL-8040 in Combination With Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma

All Publications
View All


Contact

Houston, TX 77030, US

Affiliations

  • The University Of Texas M.d. Anderson Cancer Center

Credentials

  • Licenses
    Internal Medicine in TX
  • Board Certifications
    Internal Medicine
    Hematology
    Medical Oncology

Insurance

Contact them to find out if they accept your insurance plan.